The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of Covid-19 pandemic on breast cancer multidisciplinary management at the Vall d'Hebron University Hospital.
 
Isabel Pimentel
Honoraria - Novartis
Travel, Accommodations, Expenses - Pfizer
 
Cristina Viaplana
No Relationships to Disclose
 
Carolina Ortiz
No Relationships to Disclose
 
Guillermo Villacampa
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Speakers' Bureau - MSD Oncology; Pierre Fabre
 
Juan Aguilar-Company
No Relationships to Disclose
 
Ana Rodriguez
No Relationships to Disclose
 
Victoria Magdalena Reyes
No Relationships to Disclose
 
Judith Balmana Gelpi
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - European patent request submitted (EP17382884.9) not related to this work
Travel, Accommodations, Expenses - AstraZeneca
 
Xavier Martinez
No Relationships to Disclose
 
Patricia Gómez Pardo
No Relationships to Disclose
 
Miriam Arumí
No Relationships to Disclose
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; MediTech; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Novartis; Pfizer; Puma Biotechnology; Roche
 
Martin Espinosa-Bravo
Consulting or Advisory Role - Roche; Sysmex